Dexamethasone has been shown to reduce COVID-19 related mortality, IL-6 inhibitors to reduce risk of cardiovascular or respiratory organ support, and baricitinib to reduce time to recovery in hospitalised patients requiring oxygen support [12]. Here, IL6 is linked to COVID-19.